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Abstract 
Proteinuria is routinely measured for assessment of renal allograft status, but its diagnostic 
and prognostic value for transplant pathology and outcome remain unclear.  
 We included 1518 renal allograft recipients in this prospective, observational cohort study. 
All renal allograft biopsies with concomitant data on 24h proteinuria were included in the analyses 
(N=2274). Patients were followed for at least 7 years post-transplantation.  
Compared with <0.3 g/24h, the hazard ratio for graft failure was 1.14 (95% CI 0.81-1.60; 
P=0.50) for proteinuria 0.3-1.0 g/24h, 2.17 (1.49-3.18; P<0.001) for 1.0-3.0 g/24h, and 3.01 (1.75-
5.18; P<0.001) for >3.0 g/24h, independent of glomerular filtration rate and allograft histology. The 
predictive performance of proteinuria for graft failure was low at 3 months after transplantation 
(area under the ROC curve AUC 0.64 95%CI 0.57-0.70; P<0.001), but better at later time points 
(AUC 0.73 0.66-0.80, 0.71 0.63-0.80 and 0.77 0.70-0.83, at respectively 1, 2 and 5 years after 
transplantation; all P<0.001). Independent determinants of proteinuria were repeat transplantation, 
mean arterial pressure, transplant glomerulopathy, microcirculation inflammation, and de 
novo/recurrent glomerular disease. Proteinuria showed better discriminatory power for these 
intragraft injury processes in biopsies later than 3 months after transplantation (AUC 0.73 0.68-
0.78; P<0.001) than in earlier biopsies (AUC 0.56 0.52-0.61; P=0.008), with 85% specificity but 
lower sensitivity (47.8%) of proteinuria >1.0 g/24h. 
 This analysis provides first scientific underpinning of current clinical guidelines to routinely 
measure proteinuria after transplantation. The lower sensitivity of 24h proteinuria for graft injury 
and failure illustrates the need for more sensitive biomarkers of allograft injury and prognosis.  
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INTRODUCTION 
The improvement in short-term graft attrition after kidney transplantation did not translate into 
proportionate ameliorations in long-term renal allograft survival.1 In recent years, specific diseases 
like antibody-mediated rejection and de novo/recurrent glomerular disease have been identified as 
primary causes of graft failure.2-4 The reason for insufficient improvement of renal allograft outcome 
on the long term is likely related to the inability to prevent or treat these specific diseases. In 
addition, one of the challenges for research in organ transplantation is to identify markers that are 
sufficiently diagnostic for these specific diseases, and that can be used as endpoint in clinical studies.  
 
In patients with chronic kidney disease, there is increasing interest in using the degree of proteinuria 
as surrogate endpoint for clinical trials, as proteinuria is directly related to the underlying glomerular 
disease process and strongly associates with progression to end-stage renal disease, with good 
specificity and sensitivity.5 Also in renal transplant recipients, proteinuria is routinely measured.6-8 
Proteinuria, in the nephrotic range as well as low-grade, is associated with renal allograft outcome, 
but the sensitivity and specificity of proteinuria for graft failure have not been assessed,9-11 unless in 
a cross-sectional study with low number of graft failures.12 
 
Although proteinuria has been related to de novo/recurrent glomerulonephritis or with transplant 
glomerulopathy,7-9,13-15 the association between proteinuria and the strongly evolved diagnostic 
criteria for allograft pathology, in particular criteria for antibody-mediated rejection,16,17 has not 
been considered yet. Current clinical guidelines suggest that a kidney allograft biopsy be performed 
when there is new onset of proteinuria or unexplained proteinuria ≥3.0 g/g creatinine or ≥3.0 g/24h. 
These international guidelines are however not evidence-based (evidence level 2C).18 
 
We thus aimed to assess the diagnostic and prognostic performance of measuring proteinuria after 
renal transplantation, both at time of graft dysfunction (with clinically indicated biopsies) and during 
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routine clinical follow-up (using protocol-specified biopsies). In view of the great impact of specific 
diseases like antibody-mediated rejection and de novo/recurrent glomerulonephritis on outcome 
after kidney transplantation,2-4 with new therapeutic options available, insight in the diagnostic and 
prognostic value of proteinuria for these specific diseases is particularly useful. Moreover, as many 
research teams are evaluating novel non-invasive biomarkers for renal allograft injury processes, it is 
important to fully elucidate the diagnostic and prognostic value of proteinuria measurement, a 
simple, inexpensive and non-invasive marker that is already universally available. 
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RESULTS 
Study population characteristics 
In this prospective, observational cohort study, we enrolled all consecutive recipients of a renal 
allograft transplant at University Hospitals Leuven (Leuven, Belgium) between January 1991 and 
December 2001 (N=1197) in a test Cohort 1.4 All patients who underwent single kidney 
transplantation at the same institution between March 2004 and October 2007 were included in a 
validation Cohort 2.19 The patient population characteristics are provided in Table 1 and 
Supplemental Figure 1. No cross-match positive transplantations were performed in these patients. 
In Cohort 1 (N=1197 patients), 1443 in post-transplant indication biopsies were performed in 752 
individual kidney grafts. Mean time post-transplantation of the biopsies was 1.93.4 years (range 2 
days-18.6 years). Only 78 biopsy samples (5.4%) were of insufficient quality to yield a diagnosis and 
to evaluate according to the Banff scheme,17 which left 1365 biopsies in 738 individual transplants 
for further analysis. Proteinuria measured in a 24h urine collection was available in 1335 cases (98%) 
within one week around the biopsy. Graft loss occurred in 313/1197 patients during follow-up. In 
Cohort 2 (N=321 patients), 922 post-transplant renal allograft biopsies were performed within the 
first 2 years after transplantation: 203 indication biopsies in 136 individual kidney grafts, in addition 
to 260, 257, and 202 good-quality protocol-specified biopsies at respectively 3, 12, and 24 months 
post-transplant.19 In 919/922 (99.8%; 200 indication biopsies and 719 protocol biopsies) of cases, 
concomitant 24-hours proteinuria data were available. Graft loss occurred in 45/321 patients during 
follow-up. The evolution of the histological lesions over time after transplantation in indication 
biopsies performed in Cohort 1 and in Cohort 2 has been described previously.4,19 
 
Proteinuria and kidney-allograft failure in the overall group 
For Cohort 1, mean follow-up time post-transplant of patients with a functioning graft at time of 
data extraction from the clinical database was 14.52.80 (range 10.4-20.4) years post-transplant. 
During follow-up after 1 year post-transplant, 116/619 (18.7%) patients with 24h-proteinuria ≤0.3g, 
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36/118 (30.5%) patients with 24h-proteinuria >0.3-1.0 g, 14/36 (38.9%) patients with 24h-
proteinuria >1.0-3.0g, and 4/5 (80%) patients with 24h-proteinuria >3.0 g at 1 year lost graft function 
(P<0.001). In multivariate Cox proportional-hazards analysis, the degree of proteinuria at 1, 2, and 5 
years after transplantation was associated with kidney-allograft failure, adjusted for donor and 
recipient age and gender, baseline immunosuppression, repeat transplantation, delayed graft 
function and T-cell mediated rejection, and independent of eGFR (Supplemental Table 1, Figure 1A). 
The striking association between proteinuria >3.0 g/24h at 3 months and graft failure (Figure 1A) 
was due to the underlying pathology: recurrent FSGS in 4 cases, recurrent aHUS in 2 patients, and 
transplant glomerulopathy in one patient. In the last patient, it is likely that the proteinuria at 3 
months originated from the native kidneys affected by diabetes mellitus, as proteinuria disappeared 
completely and this allograft remains functional up to the day of data extraction (16 years). 
 
In Cohort 1, at time of an indication biopsy for graft dysfunction (1335 data points), proteinuria was 
absent (<0.3 g/24h) in 665 cases (49.8%), low-grade (0.3-1.0 g/24h) in 401 cases (30.0%), moderate 
(1.0-3.0 g/24h) in 217 cases (16.3%), and severe (>3.0 g/24h) in 52 cases (3.9%). Univariate Cox 
analyses of the clinical and histological determinants of graft failure are provided in Supplemental 
Table 2. In multivariate Cox regression analysis, adjusted for donor age and time after 
transplantation, the following variables were independently associated with graft failure (Table 2): 
low eGFR at time of the biopsy, transplant glomerulopathy, microcirculation inflammation, 
polyomavirus nephropathy and interstitial fibrosis/tubular atrophy. When we added proteinuria to 
the multivariate model, proteinuria >1.0 g/24h was highly significantly associated with graft failure. 
All other associations remained statistically significant, except de novo/recurrent glomerular disease, 
which relation with graft loss was therefore fully dependent on its association with proteinuria.  
 
The Kaplan-Meier curve for graft survival stratified according to the degree of proteinuria at time of 
an indication biopsy in Cohort 1, is shown in Figure 1B. Graft survival at 5 years post-biopsy was 71%, 
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63%, 50%, and 35% for concomitant 24h proteinuria <0.3 g/24h, 0.3-1.0 g/24h, 1.0-3.0 g/24h, and 
>3.0 g/24h respectively (P<0.001). ROC analysis of 24h proteinuria for 5-year graft failure post-
biopsy yielded an AUC of 0.66 (95% CI 0.63-0.69; P<0.001). Specificity of proteinuria >1.0 g/24h for 
5-year post-biopsy failure was 86.1% (83.5%-88.4%), but sensitivity was lower (31.7%; 27.0%-
36.7%)(Figure 1C and Table 3). Predictive accuracy of 24h proteinuria at 3 months after 
transplantation was weak (AUC 0.64 95%CI 0.57-0.70; P<0.001) but increased at later time points 
(AUC 0.73 0.66-0.80, 0.71 0.63-0.80 and 0.77 0.70-0.83, at respectively 1, 2 and 5 years after 
transplantation; all P<0.001). Negative predictive value of proteinuria <1.0g/24h was high, at 91.0%-
93.1%, while the positive predictive value increased over time after transplantation, from 19.5% at 3 
months to 61.3% at 5 years post-transplantation (Figure 1D and Table 3). 
 
In Cohort 2, mean follow-up time post-transplant of patients with a functioning graft at time of data 
extraction from the clinical database was 8.61.0 (range 6.9-10.5) years post-transplant. Despite 
relatively shorter follow-up and better graft survival of the patients in Cohort 2, a similar association 
between proteinuria at 1 and 2 years after transplantation and graft failure was noted, but not at 3 
months or at time of an indication biopsy (Supplemental Table 1, Supplemental Figure 2). It should 
be noted that 88.0% (176/200) of indication biopsies in Cohort 2 were performed within the first 3 
months post-transplant. Univariate Cox analysis of the clinical and histological determinants of graft 
failure is provided in Supplemental Table 2. In multivariate analysis, the following parameters were 
independently associated with graft failure adjusted for donor age and time after transplantation: 
low eGFR, transplant glomerulopathy and interstitial fibrosis/tubular atrophy. When proteinuria was 
introduced in the multivariate model, transplant glomerulopathy was omitted from the model, 
which illustrates the interdependence of proteinuria and transplant glomerulopathy (Supplemental 
Table 3). Both in Cohort and in Cohort 2, there was no association between the use of ACE inhibitors 
or ARBs and graft failure (Supplemental Table 2).  
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Sensitivity analysis 
In the sensitivity analysis, performed in Cohort 1, we assessed the robustness of our study results by 
investigating associations separately in subgroups of patients with specific histological lesions. In 
patients with transplant glomerulopathy (N=101), the degree of moderate to severe proteinuria was 
highly significantly associated with post-biopsy graft loss: adjusted hazard ratio 1.28 (0.29-5.77; 
P=0.74) for 0.3-1.0 g/24h compared to <0.3 g/24h; 3.27 (0.87-11.9; P=0.08) for 1.0-3.0 g/24h vs. <0.3 
g/24h; and 6.59 (1.51-28.6; P=0.01) for >3.0 vs. <0.3 g/24h (Figure 1E). Graft survival at 5 years post-
diagnosis of transplant glomerulopathy was 60%, 45%, 36%, and 8% for concomitant 24h proteinuria 
<0.3 g/24h, 0.3-1.0 g/24h, 1.0-3.0 g/24h, and >3.0 g/24h respectively (P=0.005). The degree of 
proteinuria also associated significantly with the outcome after diagnosis of a de novo or recurrent 
glomerular disease (N=84) with an adjusted hazard ratio of 0.68 (0.02-19.3; P=0.82) for 0.3-1.0 
g/24h, 40.2 (3.66-440; P=0.003) for 1.0-3.0 g/24h and 79.2 (5.82-1076;P<0.001) for >3.0 g/24h, all in 
comparison with proteinuria <0.3 g/24h (Figure 1E). Graft survival at 5 years post-diagnosis of de 
novo/recurrent glomerular disease was 78%, 66%, 22%, and 21% for concomitant 24h proteinuria 
<0.3 g/24h, 0.3-1.0 g/24h, 1.0-3.0 g/24h, and >3.0 g/24h respectively (P<0.001). 
 
Renal allograft histology and proteinuria 
The univariate determinants of 24h proteinuria are provided in Supplemental Table 4. In multiple 
regression analysis (Table 4; Figure 2A-C), the independent and consistent determinants of 
proteinuria (adjusted for donor age and time after transplantation) were repeat transplantation, 
transplant glomerulopathy, microcirculation inflammation, and de novo/recurrent glomerular 
disease. In addition, also higher mean arterial pressure was associated with higher degree of 
proteinuria. This was the case both in indication and protocol biopsies (Table 4; Figure 2A-C). Despite 
the highly significant association between the presence of DSA and microcirculation inflammation 
(41% vs. 11% microcirculation inflammation in patients with vs. without DSA; P<0.001), DSA 
positivity in itself was not associated with proteinuria (Supplemental Table 4). Of note, the 
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association between glomerular abnormalities and proteinuria was marked after the first 3 months 
post-transplant, but not in the first 3 months post-transplantation (Supplemental Table 5). In Cohort 
1, there was a significant positive association between proteinuria and the use of ACE inhibitors or 
ARBs (Supplemental Table 4), which illustrates selection bias in the analyses on ACE inhibitor or ARB 
use. 
 
Proteinuria as biomarker for glomerular disease 
Next, we evaluated the diagnostic performance of proteinuria for glomerular disease in renal 
allograft biopsies. ROC curves are provided in Figure 2D-G. Proteinuria later than 3 months post-
transplant was highly significantly associated with the combined presence of either transplant 
glomerulopathy, microcirculation inflammation or de novo/recurrent glomerular disease 
(Supplemental Table 5). The ROC AUC was 0.64 (0.61-0.67; P<0.001) in Cohort 1 and 0.64 (0.58-0.70; 
P<0.001) in Cohort 2. Specificity of 24h proteinuria at time of an indication biopsy for these lesions 
was high (85.0%-91.1% for proteinuria >1.0 g/24h), but sensitivity was low (21.4%-31.7%). Early after 
transplantation, the diagnostic accuracy was low (ROC AUC 0.56 0.52-0.61 in Cohort 1). After the 
first 3 months post-transplantation in Cohort 1, the diagnostic accuracy of 24h proteinuria for either 
transplant glomerulopathy, microcirculation inflammation or de novo/recurrent glomerular disease 
was better, with a ROC AUC of 0.73 (0.68-0.78; p<0.001), a sensitivity of proteinuria >1.0 g/24h of 
47.8% (40.2%-55.4%) and a specificity of 85.2% (81.4%-88.5%) (Table 5). The number of indication 
biopsies performed later than 3 months in Cohort 2 was too low (N=26) to allow for robust statistical 
analysis in this cohort. At protocol biopsy time points, per definition performed in clinically stable 
patients (with lower degrees of proteinuria), the association between 24h proteinuria and graft 
histology was also significant, but with lower sensitivity and specificity (Table 5; Supplemental Figure 
2G). 
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DISCUSSION 
For the first time, our analysis with integration of 24h proteinuria measurement, contemporary 
detailed histological assessment, and long-term outcome data showed that proteinuria is a marker 
for graft outcome with reasonable predictive accuracy, especially later after transplantation. 
Proteinuria was highly specific for transplant glomerulopathy, microcirculation inflammation, and de 
novo/recurrent glomerular disease, both in indication and in protocol biopsies. Moreover, the 
prognosis of these specific disease processes was primarily determined by the associated degree of 
proteinuria.  
 
Although previous studies clearly illustrated that proteinuria at 3 and 12 months is associated with 
graft outcome,9,10,12 these studies did not provide insight in the value of proteinuria at time of clinical 
inquietude, when an indication biopsy is performed, or of proteinuria later after transplantation. Our 
study showed that the degree of proteinuria is a main determinant of graft failure at any time point 
after transplantation, independent of renal allograft function and independent of the underlying 
renal allograft histology. Prognosis of specific injury processes like de novo/recurrent glomerular 
disease and transplant glomerulopathy largely depended on the degree of proteinuria. Prognostic 
accuracy of proteinuria for graft failure increased over time after transplantation, with good 
specificity and high negative predictive value. Proteinuria within the first months after 
transplantation is less predictive of graft outcome, which can explain why proteinuria at indication 
biopsy time points with graft failure was not significant in Cohort 2.  
 
The high specificity of proteinuria for graft loss was counterbalanced by a relatively low sensitivity, 
which yielded a moderate overall predictive performance. The heterogeneity in the causes of graft 
failure2-4 however makes it unlikely that a single non-invasive biomarker will yield a high predictive 
performance for graft loss. It can be anticipated that only the combination of different markers that 
address this heterogeneity will yield both high sensitivity and high specificity for graft failure.  
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Next, proteinuria >1.0 g/24h was a specific non-invasive marker for highly relevant intragraft injury 
processes like microcirculation inflammation, transplant glomerulopathy, and de novo/glomerular 
disease in our study. The high specificity of proteinuria for these treatable diagnoses, both in 
indication and in protocol biopsies, provides the first evidence of current clinical guidelines that 
advocate the routine measurement of proteinuria.18 In addition, clinical guidelines suggest that a 
kidney allograft biopsy be performed when there is new onset of proteinuria or unexplained 
proteinuria ≥3.0 g/g creatinine or ≥3.0 g/24h. Our data illustrate that this threshold is very 
conservative, and that detection of proteinuria >1.0 g/24h could be a more sensitive threshold. The 
association between proteinuria and renal histology was weak in the first 3 months after 
transplantation, likely reflecting the contribution of residual renal function of the native kidneys in 
the first weeks.20,21 
 
Despite the high specificity of proteinuria for transplant glomerulopathy, microcirculation 
inflammation or glomerular disease, general diagnostic performance of 24h proteinuria for intragraft 
injury was only moderate, due to low sensitivity. Many patients with significant histologic injury did 
not have proteinuria >1.0 g/24h, illustrating that proteinuria is a late phenomenon. In specific 
populations, e.g. high-risk patients with crossmatch-positive transplantation, with de novo DSA or at 
high risk of glomerular disease recurrence, surveillance biopsies could thus be warranted in the 
absence of proteinuria or graft dysfunction, to timely detect subclinical injury.22 In this light, it seems 
surprising that the presence or occurrence of DSA did not independently associate with proteinuria 
in our study, which is in agreement with two recent studies.23,24 Although the number of patients 
positive for DSA was low in our cohort and data should thus be interpreted cautiously, it could be 
hypothesized that DSA presence does not lead to proteinuria per se, but that proteinuria appears 
only if DSA cause glomerular injury. 
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Our study has several limitations. Whether our results also apply to cross-match positive kidney 
transplants, and whether the association between histology of antibody-mediated rejection, 
proteinuria and graft outcome would be more pronounced in this specific high-risk patient cohort, 
couldn’t be inferred from our data. In addition, it should be envisaged that this study was performed 
in a European population with cross-match negative transplants, and does not represent other 
cohorts at potentially higher (immunological) risk (e.g. African Americans or positive cross-match 
transplants).25 Moreover, the absence of DSA testing in Cohort 1 obviates a thorough insight in the 
association of DSA on very long-term histology and graft outcome. To fully appreciate the diagnostic 
and prognostic importance of 24h proteinuria in renal transplantation, repeating these analyses and 
validation in a population at higher immunological risk should be considered.  
 
It has been shown that mTOR inhibitor use can lead to proteinuria,26 but we did not observe this in 
our analysis, likely due to the very low number of patients treated with mTOR inhibitors in our 
cohorts. Furthermore, in Cohort 2, the association between proteinuria and graft failure was less 
significant than in Cohort 1, which likely relates to the overall better outcome in this more recent 
and smaller cohort, and to shorter follow-up time. Although proteinuria in 24h urine collections 
remains the reference method for quantification of proteinuria, it is cumbersome in clinical practice. 
Many centers use the proteinuria/creatinine ratio in spot urine samples to overcome this burden. 
Whether the diagnostic and prognostic importance of spot urine protein excretion is comparable to 
the value of 24h proteinuria, remains to be evaluated. Protein/creatinine levels in spot urine 
samples were not available in this study. In addition, we have no data on albuminuria or proteinuria 
composition, which could potentially discriminate between glomerular and tubular origin of the 
proteinuria, and could be a better marker in patients with total proteinuria <0.3 g/24h.12,27,28 Finally, 
the potential benefit of RAS inhibitor use29 in kidney transplant patients could not be evaluated in 
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our observational cohort study with inherent selection bias, as patients with proteinuria were more 
likely to receive RAS inhibitors compared to non-proteinuric patients.  
 
In conclusion, this analysis of the diagnostic performance of proteinuria for treatable disease 
processes (transplant glomerulopathy, microcirculation inflammation and de novo or recurrent 
glomerular disease), both in indication and in protocol biopsies, provides first scientific underpinning 
of current clinical guidelines to routinely measure proteinuria after transplantation, and to pursue a 
histological diagnosis when proteinuria >1.0 g/24h is detected. The low sensitivity of 24h proteinuria 
for graft injury and failure illustrates the need for novel, more sensitive non-invasive biomarkers of 
kidney graft injury and prognosis.  
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CONCISE METHODS 
Clinical data and proteinuria 
All data were collected from the day of transplantation until time of data extraction, during the 
routine clinical follow-up of the transplant recipients. This study was approved by the Ethics 
Committee of the University Hospitals Leuven (S53364; ML7499). The clinical data in both cohorts 
were prospectively collected in electronic clinical patient charts, which were used for clinical patient 
management as well as were directly linked to the database used in this study. This clinical database 
was transferred to SAS data files (SAS institute, Cary, NC) at time of analysis. Proteinuria was 
assessed in 24h urine collections (total proteinuria/24h) at 3 months, and at 1, 2, 5, and 10 years 
after transplantation, and at time of a renal allograft biopsy. Urinary 24-hour protein excretion 
remains the reference method for quantification of proteinuria in patients with 
glomerulonephritis.30 Proteinuria was graded as absent (≤0.3 g/24h), mild (>0.3-1.0 g/24h), 
moderate (>1.0-3.0 g/24h), and severe (>3.0 g/24h)7. Renal allograft function (eGFR) was estimated 
using the 4-variable MDRD formula.31 Spot urine data on protein/creatinine levels were not available 
in these cohorts.  
 
Biopsies and histological scoring 
All post-transplant renal allograft biopsies performed in this cohort, until time of data extraction, 
were included. In Cohort 1, post-transplant biopsies were performed for clinical indication only. No 
post-transplant surveillance biopsies were performed in this cohort. In Cohort 2, protocol-specified 
biopsies were performed systematically at 3, 12 months, and 24 months after transplantation, in 
addition to the clinically indicated biopsies (“indication biopsies”).  
 
Slides were stained with hematoxylin eosin (HE), Periodic Acid-Schiff (PAS) and silver methenamine 
(Jones). An immunohistochemical C4d stain (monoclonal antibody, dilution 1:500, Quidel 
Corporation, Santa Clara, CA) was performed on frozen tissue. One pathologist (EL) retrospectively 
 16 
reviewed all biopsies, blinded for the timing of the biopsy and for the clinical data. The severity of 
histological lesions was semi-quantitatively rescored according to the revised Banff criteria.17 In 
addition, the number of sclerosed glomeruli was scored separately (0=0%; 1=1-25%; 2=25-50%; 
3=>50% glomerulosclerosis). The microcirculation inflammation score was defined as the sum of the 
Banff glomerulitis and peritubular capillaritis scores (range 0-6). Data on donor-specific HLA 
antibodies (DSA) were not available for Cohort 1. In Cohort 2, systematic follow-up HLA antibodies 
(ELISA HLA class I and class II Gen-Probe LifeCodes technique before 2008; since 2008 Luminex Gen-
Probe LifeCodes LSA screening) and their donor-specificity in case of positive screening (using 
Luminex Gen-Probe LifeCodes LSA Single Antigen beads) were evaluated at time of protocol biopsies 
and also for clinical indication (in combination with indication biopsies).  
 
Data collection and statistical analysis 
For variance analysis of continuous variables in different groups, non-parametric Wilcoxon-Mann-
Whitney U, non-parametric ANOVA and parametric one-way ANOVA were used. Dichotomous 
variables were compared using the chi-square test. For assessing the clinical and histological 
determinants of proteinuria, univariate and multivariate mixed-models repeated-measures analyses 
were used with an unstructured covariance matrix. Receiver operating characteristic (ROC) analysis 
was performed to evaluate diagnostic accuracy and to calculate specificity and sensitivity (with 95% 
confidence intervals). Univariate and multivariate Cox proportional-hazards analysis, Kaplan–Meier 
analysis, and log-rank tests were used to examine the association between proteinuria and graft 
failure. In case of death with a functioning graft, we censored graft survival at time of death. To 
account for repeat biopsies within the same patient, the counting process model was used in the 
Cox proportional-hazards models. The data for each subject with multiple events was described as 
data for multiple subjects where each has delayed entry and is followed until the next event. 
Survival analyses were confined to the first 10 years after the biopsy, with kidney-graft loss as the 
event of interest. Repeat transplants within the inclusion time frame were regarded as separate 
 17 
entities in statistical analysis. Log(-log(survival)) versus log(time) plots showed no non-
proportionality of hazards. Patients with missing values were excluded from the analysis. All tests 
were two-sided and P values of less than 0.05 were considered to indicate statistical significance. 
Factors with a P value <0.2 in univariate analyses were entered in hypothesis-generating 
multivariate analyses, with backward selection of the final model. We used SAS software (version 
9.3; SAS institute, Cary, NC), for the statistical analyses and GraphPad Prism (version 6; GraphPad 
Software, San Diego, CA), for data presentation. This study had no external funding. 
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FIGURE LEGENDS 
Figure 1. The Degree of Proteinuria Associates with Graft Survival 
(A) Kaplan-Meier survival curve for the association between 24h proteinuria at different time points 
after transplantation, and graft survival in the unselected cohort of 1197 kidney recipients. (B) 
Kaplan-Meier survival curve for the association between 24h proteinuria at time of an indication 
biopsy and post-biopsy graft failure. (C) Receiver operating characteristic (ROC) curve of the 
association between proteinuria and post-biopsy graft failure. (D) ROC curve of the association 
between proteinuria measured at different time points after transplantation, and graft failure 5 
years later. (E) Kaplan-Meier survival curves for graft survival according to the degree of proteinuria 
at time of a biopsy with transplant glomerulopathy and at time of diagnosis of de novo/recurrent 
glomerular disease. cg= transplant glomerulopathy; glom.dis. = de novo/recurrent glomerular 
disease, prot. = proteinuria 
 
Figure 2. Proteinuria is a Marker of Renal Allograft Histology 
(A-B) Association between clinical and histological parameters and 24h proteinuria in Cohort 1 (A; 
N=1335 indication biopsies) and in Cohort 2 (B-C; N=919 biopsies, 200 indication biopsies and 719 
protocol biopsies). These parameters were independently and consistently associated with 24h 
proteinuria in mixed-model repeated-measures analysis (Table 4). (D) Receiver operating 
characteristic (ROC) curve of the association between 24h proteinuria and the presence of 
transplant glomerulopathy, microcirculation inflammation and/or de novo/recurrent glomerular 
disease in the concomitant renal allograft biopsy in Cohort 1 (N=1335). (E) ROC curve of the 
association between 24h proteinuria and the presence of transplant glomerulopathy, 
microcirculation inflammation and/or de novo/recurrent glomerular disease in the concomitant 
renal allograft biopsy (both protocol-specified and clinically indicated) in Cohort 2 (N=919). (F-G) 
ROC curves of the association between 24h proteinuria and the presence of transplant 
glomerulopathy, microcirculation inflammation and/or de novo/recurrent glomerular disease in the 
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concomitant renal allograft biopsy, in the indication (F; N=200) and protocol (G; N=719) biopsies of 
Cohort 2.
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Table 1. Patient Demographics  
 
 Cohort 1 
(1991-2001) 
Cohort 2 
(2004-2007) 
P value 
Number of patients 1197 321  
Recipient characteristics    
   Recipient age 49.1 ± 13.3 53.9 ± 13.6 <0.001 
   Recipient gender (male) 698 (58.3%) 197 (61.4%) 0.32 
   Recurrence potential of primary renal disease
a
 390 (32.6%) 79 (24.6%) 0.006 
   Caucasian ethnicity 1149 (96.0%) 295 (91.9%) 0.003 
   Repeat transplantation  148 (12.4%) 45 (14.0%) 0.43 
   Pretransplant donor-specific antibodies -- 17 (5.3%) -- 
   Number of HLA mismatches 2.57 ± 1.30 2.45 ± 1.30 0.28 
   Treatment with tacrolimus + MMF + steroids 261 (21.8%) 230 (71.7%) <0.001 
   Treatment with an mTOR inhibitor -- 18 (5.6%) -- 
   Additional induction therapy 168 (14.0%) 135 (42.1%) <0.001 
Donor characteristics    
   Donor age 38.8 ± 15.6 46.3 ± 15.0 <0.001 
   Donor gender (male) 747 (62.4%) 184 (57.3%) 0.10 
   Deceased donor 1186 (99.1%) 302 (94.1%) <0.001 
   Cold ischemia time (hours) 18.4 ± 4.94 14.7 ± 5.88 <0.001 
Post-transplant data    
   Delayed graft function 166 (13.9%) 47 (14.6%) 0.72 
   Donor-specific antibodies at 1 year -- 18/257 (7.0%) -- 
   Donor-specific antibodies at 2 years -- 16/202 (7.9%) -- 
   eGFR at 1 year (mL/min/1.73m
2
) 45.3 ± 15.6 55.7 ± 18.2 <0.001 
   eGFR at 2 years (mL/min/1.73m
2
) 45.7 ± 17.2 55.6 ± 18.2 <0.001 
   eGFR at 10 years (mL/min/1.73m
2
) 46.5 ± 20.2 -- -- 
   Proteinuria (g/24h) at 1 year 0.27 ± 0.59 0.23 ± 0.64 0.38 
   Proteinuria (g/24h) at 2 years 0.27 ± 0.60 0.20 ± 0.35 0.11 
   Proteinuria (g/24h) at 10 years 0.37 ± 0.65 -- -- 
   1-year dialysis-free patient survival 90.4% 96.3% <0.001 
   5 -year dialysis-free patient survival 78.4% 85.7% 0.004 
   10-year dialysis-free patient survival 59.9% -- -- 
   1-year graft survival
b
 93.6% 96.9% 0.03 
   5-year graft survival
b
 86.2% 91.4% 0.02 
   10-year graft survival
b
 74.8% -- -- 
 
aRenal diseases with recurrence potential were primary FSGS, idiopathic membranous 
nephropathy, IgA nephropathy, membranoproliferative glomerulopathy, nephropathy 
associated with systemic lupus erythematosis, ANCA-associated vasculitis, anti-GBM disease, 
Henoch-Schönlein purpura nephropathy, hemolytic uremic syndrome, amyloidosis, 
monoclonal immunoglobulin deposition disease and primary glomerulonephritis without 
clear diagnosis. bGraft survival was censored at time of recipient death.
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Table 2. Hazard Ratio (Multivariate Models) for Graft Failure According to Renal Allograft Histology, Renal Function and Proteinuria at Time of Biopsy, 
Adjusted for Donor Age and Time after Transplantation in Cohort 1 (N=1335 Indication Biopsies).  
 
 Parameter Adjusted Hazard Ratio (95% CI) P value  
MODEL 1 WITHOUT PROTEINURIA    
eGFR at time of biopsy 30-45 vs. >45 mL/min/m2 1.48 (0.50-4.40) 0.48 
 15-30 vs. >45 mL/min/m2 4.21 (1.53-11.6) 0.006 
 <15 vs. >45 mL/min/m2 9.41 (3.37-26.3) <0.001 
Microcirculation inflammation g+ptc 2 vs. <2 1.45 (1.03-2.04) 0.03 
IF/TA grade Banff grade 1 vs. 0 1.72 (1.19-2.50) 0.004 
 Banff grade 2-3 vs. 0 3.44 (2.34-5.05) <0.001 
Transplant glomerulopathy Banff grade 1 vs. 0 1.24 (0.69-2.22) 0.48 
 Banff grade 2-3 vs. 0 2.54 (1.54-4.18) <0.001 
De novo/recurrent glomerular disease Present vs. absent 1.59 (0.99-2.56) 0.06 
Polyomavirus associated nephropathy Present vs. absent 5.84 (3.22-10.6) <0.001 
    
MODEL 2 WITH PROTEINURIA    
Proteinuria at time of biopsy 0.3-1.0 vs. <0.3 g/24h 1.14 (0.81-1.60) 0.50 
 1.0-3.0 vs. <0.3 g/24h 2.17 (1.49-3.18) <0.001 
 >3.0 vs. <0.3 g/24h 3.01 (1.75-5.18) <0.001 
eGFR at time of biopsy 30-45 vs. >45 mL/min/m2 1.76 (0.59-5.30) 0.31 
 15-30 vs. >45 mL/min/m2 5.53 (1.99-15.4) 0.001 
 <15 vs. >45 mL/min/m2 11.7 (4.17-33.0) <0.001 
Microcirculation inflammation g+ptc 2 vs. <2 1.36 (0.97-1.91) 0.07 
IF/TA grade Banff grade 1 vs. 0 1.82 (1.25-2.64) 0.002 
 Banff grade 2-3 vs. 0 3.45 (2.34-5.07) <0.001 
Transplant glomerulopathy Banff grade 1 vs. 0 1.00 (0.55-1.82) 0.99 
 Banff grade 2-3 vs. 0 1.83 (1.11-3.04) 0.02 
De novo/recurrent glomerular disease Present vs. absent 1.35 (0.84-2.19) 0.22 
Polyomavirus associated nephropathy Present vs. absent 5.51 (3.06-9.92) <0.001 
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Table 3. Predictive performance of 24h proteinuria for graft failure in receiver operating characteristic (ROC) analysis in Cohort 1.  
 
GRAFT FAILURE AT 5 YEARS AFTER PROTEINURIA MEASUREMENT 
 
AUC P value Sensitivity Specificity PPV NPV 
3 months post-transplant (N=914) 
      
   Proteinuria >1.0 g/24h 
0.64 (0.57-0.70) <0.001 
10.1% (4.47%-19.0%) 95.3% (93.7%-96.7%) 19.5% 91.2% 
   Proteinuria >3.0 g/24h 5.06% (1.40%-12.5%) 99.5% (98.8%-99.9%) 50.0% 91.1% 
1 year post-transplant (N=778) 
    Proteinuria >1.0 g/24h 
0.73 (0.66-0.80) <0.001 
16.4% (8.15%-28.1%) 95.5% (93.8%-96.9%) 26.3% 92.6% 
   Proteinuria >3.0 g/24h 4.92% (1.03%-13.7%) 99.6% (98.8%-99.9%) 60.0% 91.9% 
2 years post-transplant (N=731) 
    Proteinuria >1.0 g/24h 
0.71 (0.63-0.80) <0.001 
20.0% (10.4%-33.0%) 95.6% (93.7%-97.0%) 30.6% 93.1% 
   Proteinuria >3.0 g/24h 5.45% (1.14%-15.1%) 99.4% (98.5%-99.8%) 50.0% 92.2% 
5 years post-transplant (N=637) 
    Proteinuria >1.0 g/24h 
0.77 (0.70-0.83) <0.001 
28.4% (18.0%-40.7%) 96.4% (94.5%-97.7%) 61.3% 91.0% 
   Proteinuria >3.0 g/24h 4.48% (0.93%-12.5%) 99.8% (99.0%-100%) 100% 88.6% 
GRAFT FAILURE AT 5 YEARS AFTER INDICATION BIOPSY 
 
AUC P value Sensitivity Specificity PPV NPV 
All biopsies (N=1335) 
      
   Proteinuria >1.0 g/24h 
0.66 (0.63-0.69) <0.001 
31.7% (27.0%-36.7%) 86.1% (83.5%-88.4%) 51.5% 73.2% 
   Proteinuria >3.0 g/24h 7.32% (4.88-10.5%) 97.9% (96.6%-98.8%) 63.0% 69.6% 
Biopsies < 3 months post-transplant (N=752) 
    Proteinuria >1.0 g/24h 
0.62 (0.57-0.67) <0.001 
25.9% (19.4%-33.3%) 87.2% (84.0%-89.9%) 38.7% 78.4% 
   Proteinuria >3.0 g/24h 2.41% (0.66-6.05%) 98.3% (96.7%-99.2%) 35.7% 75.8% 
Biopsies > 3 months post-transplant (N=583) 
    Proteinuria >1.0 g/24h 
0.71 (0.67-0.76) <0.001 
36.5% (29.8%-43.5%) 84.8% (80.0%-88.7%) 63.6% 65.1% 
   Proteinuria >3.0 g/24h 10.8% (6.92%-16.0%) 97.2% (94.5%-98.8%) 75.0% 60.5% 
PPV = positive predictive value; NPV = negative predictive value 
 27 
Table 4. Determinants of Proteinuria in Multivariate Mixed Model Analysis, in Cohort 1 (N=1335 Indication Biopsies) and in Cohort 2 (N=919 Indication 
and Protocol Biopsies). Univariate analyses are provided in Supplemental Table 4. 
 
  Cohort 1 (N=1335 indication biopsies) Cohort 2 (N=919 indication and protocol biopsies) 
Parameter Estimate Standard Error t value P value Estimate Standard Error t value P value 
Mean arterial pressure at time of biopsy 
   
  
    
>median vs. <median
b
 0.26 0.06 4.14 <0.001 0.10 0.04 2.64 0.009 
Donor age 
   
  
    
40-60 years vs. <40 years -0.17 0.08 -2.27 0.02 --
a
 --
a
 --
a
 --
a
 
>60 years vs. <40 years -0.28 0.11 -2.55 0.01 --
 a
 --
 a
 --
 a
 --
 a
 
Repeat transplantation 
   
  
    
Yes vs. no 0.41 0.10 4.06 <0.001 0.13 0.07 1.97 0.050 
Microcirculation inflammation 
   
  
    
 0.17 0.08 2.22 0.03 0.18 0.06 2.93 0.004 
Transplant glomerulopathy 
   
  
    
Banff grade >0 vs. 0 0.80 0.18 4.50 <0.001 0.88 0.15 5.94 <0.001 
De novo/recurrent glomerular disease 
   
  
    
Present vs. absent 0.97 0.17 5.78 <0.001 0.46 0.13 3.56 <0.001 
Interstitial inflammation 
   
  
    
Banff grade 1 vs. 0 --
a
 --
a
 --
a
 --
a
 0.16 0.06 2.67 0.008 
Banff grade 2-3 vs. 0 --
 a
 --
 a
 --
 a
 --
 a
 0.15 0.06 2.48 0.01 
Vascular intimal thickening 
   
  
    
Banff grade 1 vs. 0 -0.05 0.10 -0.55 0.59 --
a
 --
a
 --
a
 --
a
 
Banff grade 2-3 vs. 0 0.37 0.12 3.12 0.002 --
 a
 --
 a
 --
 a
 --
 a
 
a
Parameter not included in the final model after backward parameter selection. 
b
Median mean arterial pressure was 103 mm Hg in Cohort 1 and 96 mm Hg in Cohort 2. 
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Table 5. Diagnostic performance of 24h proteinuria for the combination of transplant glomerulopathy, de novo/recurrent glomerular disease and/or 
microcirculation inflammation (g+ptc  2) in receiver operating characteristic (ROC) analysis in Cohort 1 (N=1335) and Cohort 2 (N=919).  
 
 Transplant glomerulopathy, glomerular disease and/or microcirculation inflammation 
  AUC P value Sensitivity Specificity PPV NPV 
COHORT 1 
      
All biopsies (N=1335) 
      
    Proteinuria >1.0 g/24h 
0.64 (0.61-0.67) <0.001 
31.7% (27.1%-36.5%) 85.0% (82.6%-87.2%) 47.2% 74.3% 
    Proteinuria >3.0 g/24h 7.98% (5.52%-11.1%) 98.1% (97.0%-98.9%) 65.4% 71.4% 
Biopsies < 3 months post-transplant (N=752) 
     Proteinuria >1.0 g/24h 
0.56 (0.52-0.61) 0.008 
18.8% (13.9%-24.6%) 84.9% (81.5%-87.8%) 34.1% 71.2% 
    Proteinuria >3.0 g/24h 2.69 (0.99%-2.76%) 98.5% (97.0%-99.3%) 40.0% 70.6% 
Biopsies > 3 months post-transplant (N=583) 
     Proteinuria >1.0 g/24h 
0.73 (0.68-0.78) <0.001 
47.8% (40.2%-55.4%) 85.2% (81.4%-88.5%) 58.2% 78.7% 
    Proteinuria >3.0 g/24h 14.6% (9.77%-20.7%) 97.8% (95.8%-98.9%) 75.7% 72.5%  
COHORT 2 
      All biopsies (N=919) 
     
     Proteinuria >1.0 g/24h 
0.64 (0.58-0.70) <0.001 
12.5% (7.17%-19.8%) 97.1% (95.7%-98.2%) 39.5% 88.1% 
    Proteinuria >3.0 g/24h 2.50% (0.52%-7.13%) 99.8% (99.1%-100%) 50.0% 87.2% 
Indication biopsies (N=200) 
     Proteinuria >1.0 g/24h 
0.64 (0.55-0.73) 0.005 
21.4% (10.3%-36.8%) 91.1% (85.6%-95.1%) 39.1% 81.4% 
    Proteinuria >3.0 g/24h 2.38% (0.06%-12.6%) 99.4% (96.5-100%) 33.3% 79.2% 
Protocol-specified biopsies (N=719) 
     Proteinuria >1.0 g/24h 
0.59 (0.52-0.66) 0.008 
7.69% (2.88%-16.0%) 98.6% (97.4%-99.4%) 40.0% 89.8% 
    Proteinuria >3.0 g/24h 2.56% (0.31%-8.96%) 99.8% (99.1%-100%) 66.7% 89.4% 
 
PPV = positive predictive value; NPV = negative predictive value. 
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SUPPLEMENTAL MATERIAL 
 
Supplemental Figure 1. Overview of the patients and biopsies included. In Cohort 1, renal allograft biopsies were 
performed for clinical indication only. In Cohort 2, biopsies were performed at pre-specified time points after 
transplantation (protocol-specified biopsies at 3, 12, and 24 months after transplantation) and for clinical indication. 
Proteinuria measurements in 24h urine collections were performed at time of a protocol-specified biopsy, or within 
one week around an indication biopsy. 
 
Supplemental Figure 2. Kaplan Meier survival curves for graft survival according to degree of proteinuria in Cohort 2 
at 3 months, 1 and 2 years after Transplantation, and at time of an indication biopsy.  
 
Supplemental Table 1. Hazard Ratio (multivariate models) for Graft Failure According to Renal Function and 
Proteinuria at 1, 2 and 5 Years after Transplantation in Cohort 1. 
 
Supplemental Table 2. Hazard ratio (univariate models) for post-biopsy graft failure, according to individual clinical 
and histological parameters in Cox proportional hazards analysis in Cohort 1 and 2. 
 
Supplemental Table 3. Hazard ratio (multivariate models) for graft failure according to renal allograft histology, renal 
function and proteinuria at time of biopsy, adjusted for donor age and time after transplantation in Cox proportional 
hazards analysis (Cohort 2; N=919 biopsies).  
 
Supplemental Table 4. Univariate analysis of the determinants of 24h proteinuria in Cohort 1 (N=1335 indication 
biopsies) and in Cohort 2 (N= 919 indication and protocol biopsies). 
 
Supplemental Table 5. Association between proteinuria and concomitant renal graft histology after transplantation 
according to time after transplantation in Cohort 1 (N=1335 indication biopsies).  
